Lung Cancer: Causes, Diagnosis, Treatment

(Note: For PDF File Swipe To The End Of Article)

Introduction

Lung cancer is a malignant disease that develops when abnormal cells in the lungs begin to grow uncontrollably, evade normal mechanisms of cell death, invade surrounding tissues, and potentially spread to distant organs. It is one of the most important cancers worldwide because of its high incidence, substantial mortality, and strong association with preventable environmental exposures. In 2022, approximately 2.5 million people were diagnosed with lung cancer globally, while more than 1.8 million people died from the disease. Tobacco smoking remains the principal risk factor, although lung cancer also occurs in people who have never smoked.

The lungs are particularly vulnerable to carcinogenic injury because every breath brings air and potentially harmful particles into direct contact with the respiratory epithelium. Cigarette smoke contains numerous carcinogens capable of producing DNA damage. Repeated exposure can cause genetic and epigenetic alterations, abnormal cellular proliferation, and eventually malignant transformation. However, lung cancer is not simply a disease of smokers. Second-hand smoke, radon, asbestos, air pollution, occupational exposures, previous lung disease, and inherited or acquired genetic susceptibility can also contribute to its development.

Lung cancer is broadly divided into two major categories: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC is more common and includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, among other less common forms. SCLC is characterized by rapid growth and an early tendency to metastasize.

The clinical presentation varies considerably. Some patients have no symptoms during the early stages, and a tumor may be discovered incidentally during imaging performed for another reason. Others develop persistent cough, hemoptysis, chest pain, breathlessness, wheezing, hoarseness, unexplained weight loss, fatigue, or recurrent respiratory infections. When the disease spreads beyond the lungs, symptoms may reflect involvement of the brain, bones, liver, adrenal glands, or other organs.

Modern lung cancer management has changed substantially. Treatment is no longer based only on the location and size of a tumor. Histological classification, molecular alterations, biomarker expression, stage, performance status, comorbidities, and the patient's overall goals are increasingly important. Depending on the circumstances, treatment may include surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, or combinations of these approaches.

Understanding Normal Lung Anatomy

To understand lung cancer, it is useful to understand the normal structure of the respiratory system. The lungs are paired organs located within the thoracic cavity. The right lung has three lobes, while the left lung has two lobes and a cardiac indentation that accommodates the heart.

Air enters through the nose or mouth and passes through the pharynx and larynx into the trachea. The trachea divides into the right and left main bronchi, which progressively branch into smaller bronchi and bronchioles. The terminal bronchioles ultimately lead to respiratory bronchioles, alveolar ducts, and alveoli.

The alveoli are microscopic air sacs surrounded by an extensive capillary network. Their thin walls allow oxygen to diffuse into the blood and carbon dioxide to diffuse from the blood into the alveolar air. The respiratory epithelium therefore performs an essential physiological function while simultaneously serving as a major interface between the body and inhaled environmental substances.

The lungs are covered by the visceral pleura, while the inner surface of the chest wall is lined by the parietal pleura. Between these layers is the pleural cavity, which normally contains a small amount of lubricating fluid. Lung tumors can invade the pleura and produce pleural effusion, chest discomfort, or impaired lung expansion.

The bronchial tree is clinically important in lung cancer because tumors can arise in different anatomical locations. Some tumors develop near the central bronchi, whereas others arise in peripheral lung tissue. The location influences symptoms, imaging appearance, biopsy technique, surgical options, and potential complications.

The lungs also contain an extensive lymphatic network. Lymphatic drainage from a tumor can carry malignant cells to regional lymph nodes. This is one reason lymph-node involvement is an important component of lung cancer staging.

What Is Lung Cancer?

Lung cancer occurs when cells within the lung acquire abnormalities that allow them to proliferate independently of normal regulatory mechanisms. Normal cells generally divide in a controlled manner, repair DNA damage when possible, and undergo programmed cell death when they become severely damaged. Cancer cells progressively lose these controls.

Cancer development is usually a multistep process rather than a single event. Repeated exposure to carcinogens can cause mutations in genes controlling cell growth, DNA repair, apoptosis, and interactions with the immune system. Additional molecular alterations may accumulate over time, producing cells with increasingly aggressive biological behavior.

A malignant tumor can grow locally, invade nearby structures, enter blood vessels or lymphatic channels, and establish secondary tumors elsewhere in the body. This process is known as metastasis.

The biological behavior of lung cancer differs significantly between patients. Two tumors of similar size may behave differently because they have different histological and molecular characteristics. This explains why modern diagnosis increasingly incorporates molecular testing and biomarker analysis.

Major Types of Lung Cancer

Lung cancers are primarily classified into non-small cell lung cancer and small cell lung cancer. This distinction is clinically important because the two categories differ in morphology, growth rate, patterns of spread, staging systems, and treatment strategies.

Non-Small Cell Lung Cancer

Non-small cell lung cancer accounts for the majority of lung cancers. It includes several histological subtypes.

The major types include:

• Adenocarcinoma
• Squamous cell carcinoma
• Large cell carcinoma

Other less common forms include adenosquamous carcinoma, sarcomatoid carcinoma, salivary-gland-type tumors, and other uncommon histological variants.

Adenocarcinoma

Adenocarcinoma is a gland-forming epithelial malignancy and is commonly found in the peripheral portions of the lung. It may occur in smokers as well as people who have never smoked.

Adenocarcinoma has become particularly important because some tumors contain actionable molecular alterations. Examples include abnormalities involving genes such as EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, KRAS, and others. Identification of an actionable alteration can significantly influence treatment selection.

Because adenocarcinoma can occur in never-smokers, the absence of a smoking history does not eliminate the possibility of lung cancer.

Squamous Cell Carcinoma

Squamous cell carcinoma is strongly associated with cigarette smoking. It often arises in the central airways and may form a mass near a major bronchus.

Because of its central location, it may produce symptoms related to airway obstruction. These can include persistent cough, wheezing, recurrent pneumonia, or hemoptysis.

Squamous tumors can also cause metabolic complications. Some produce parathyroid hormone-related protein, resulting in hypercalcemia of malignancy.

Large Cell Carcinoma

Large cell carcinoma is a poorly differentiated form of NSCLC characterized by malignant cells that lack the specific microscopic features required to classify them as other major subtypes. It is less common than adenocarcinoma or squamous cell carcinoma.

These tumors can be aggressive and may occur in either central or peripheral regions of the lung.

Small Cell Lung Cancer

Small cell lung cancer is a distinct and aggressive form of lung cancer. It is strongly associated with tobacco exposure and is characterized by rapid growth, early spread, and high sensitivity to chemotherapy and radiation compared with many other lung cancers.

Microscopically, the tumor consists of small malignant cells with scant cytoplasm and characteristic nuclear features.

SCLC frequently spreads to lymph nodes and distant organs. Common metastatic sites include the brain, liver, bones, adrenal glands, and other areas.

Because SCLC tends to disseminate early, treatment is generally based on systemic therapy rather than surgery alone.

SCLC is traditionally categorized as limited-stage or extensive-stage disease, although modern clinical practice also incorporates more detailed anatomical and imaging information.

Causes and Risk Factors

Lung cancer is caused by accumulated cellular damage and genetic alterations. Tobacco exposure is the dominant preventable cause, but multiple other risk factors contribute. IARC reports that smoking is responsible for approximately 85% of lung cancer cases, while additional contributors include second-hand smoke, air pollution, asbestos, diesel exhaust, and welding fumes.

Cigarette Smoking

Cigarette smoking is the most important risk factor for lung cancer. Tobacco smoke contains numerous carcinogenic substances, including polycyclic aromatic hydrocarbons and tobacco-specific nitrosamines.

Risk increases with cumulative exposure. A useful clinical concept is pack-years, calculated as:

Pack-years = packs smoked per day × years smoked

For example, smoking one pack per day for 20 years equals 20 pack-years.

However, pack-years should not be interpreted as a threshold below which lung cancer cannot occur. Even people with relatively low exposure can develop cancer.

Smoking also increases the risk of several other diseases, including chronic obstructive pulmonary disease, cardiovascular disease, and multiple other malignancies.

Passive Smoking

Second-hand smoke exposure is also associated with lung cancer. People who do not smoke may inhale tobacco smoke produced by others, resulting in exposure to carcinogenic compounds.

This is particularly important in households, workplaces, and other environments where tobacco exposure is frequent.

Radon Exposure

Radon is a naturally occurring radioactive gas that can accumulate in buildings, particularly in poorly ventilated areas. Its radioactive decay products can damage respiratory epithelial cells.

Radon exposure is an important environmental cause of lung cancer and can interact with smoking to increase overall risk.

Occupational Exposures

Certain occupations involve exposure to substances associated with lung carcinogenesis. These include:

• Asbestos
• Silica
• Arsenic
• Chromium
• Nickel
• Coal-related dust
• Diesel exhaust
• Certain industrial fumes

Occupational risk is particularly important when exposure is prolonged or poorly controlled.

Asbestos

Asbestos exposure is strongly associated with several thoracic malignancies, including lung cancer and malignant mesothelioma.

The risk of lung cancer among people exposed to asbestos is particularly concerning when combined with cigarette smoking.

Air Pollution

Outdoor and indoor air pollution can contain fine particulate matter and carcinogenic compounds. Long-term exposure to polluted air has been associated with increased lung cancer risk.

Air pollution is especially relevant in heavily industrialized or densely populated areas.

Previous Lung Disease

Some chronic pulmonary conditions may be associated with increased lung cancer risk. Chronic inflammation, scarring, fibrosis, and repeated tissue injury can create an environment in which abnormal cellular changes develop.

However, having a chronic lung disease does not mean that a person will necessarily develop cancer.

Family History and Genetic Susceptibility

A family history of lung cancer may increase risk, although many lung cancers occur without a strong family history.

Genetic susceptibility may influence how an individual's body responds to carcinogens and how efficiently damaged DNA is repaired.

How Lung Cancer Develops

The development of lung cancer can be understood as a progression from normal cells through genetic and cellular abnormalities toward invasive malignancy.

Carcinogens can directly or indirectly damage DNA. If DNA repair mechanisms fail to correct the damage, mutations may persist when the cell divides.

Mutations affecting growth-promoting genes can cause excessive cellular proliferation. Alterations in tumor-suppressor genes can remove important restraints on cell division. Abnormalities in apoptosis may allow damaged cells to survive when they should normally die.

As abnormal cells accumulate additional changes, they may acquire several important characteristics of cancer:

• Uncontrolled proliferation
• Resistance to programmed cell death
• Ability to stimulate blood-vessel formation
• Ability to invade surrounding tissues
• Ability to evade immune responses
• Ability to spread through blood and lymphatic vessels

Eventually, a malignant tumor may form.

The tumor can remain localized for some time, but invasive cancer has the potential to spread through lymphatic channels and blood vessels. Metastatic disease represents a major change in the clinical situation because treatment often becomes systemic rather than purely local.

Molecular Changes in Lung Cancer

Modern lung cancer care increasingly recognizes that cancer is not a single molecular disease. Different tumors can contain different driver alterations.

In NSCLC, molecular testing may identify changes that influence treatment. Examples include alterations involving EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, and NTRK, among others.

Another important biomarker is PD-L1 expression, which can help inform decisions about immunotherapy in appropriate patients.

Molecular testing is particularly important in advanced NSCLC because targeted treatments may be available for specific genomic alterations. NCI notes that tumor-genomic changes and PD-L1 expression are important considerations in selecting therapy for advanced NSCLC.

This approach is an example of precision oncology, in which treatment is selected according to the biological characteristics of an individual tumor rather than relying exclusively on its anatomical location.

Clinical Features of Lung Cancer

Lung cancer may remain silent during its early stages. Symptoms often become apparent when the tumor grows sufficiently to obstruct an airway, invade surrounding structures, cause inflammation, produce systemic effects, or spread to distant organs.

Common respiratory symptoms include:

• Persistent cough
• Worsening chronic cough
• Hemoptysis
• Shortness of breath
• Wheezing
• Chest discomfort
• Recurrent respiratory infections
• Hoarseness

Systemic symptoms may include:

• Unexplained weight loss
• Reduced appetite
• Fatigue
• General weakness
• Malaise

NCI lists persistent or worsening cough, difficulty breathing, wheezing, blood in sputum, hoarseness, chest discomfort, unexplained weight loss, fatigue, and other symptoms among possible manifestations of NSCLC.

Importantly, these symptoms are not specific to cancer. They can occur with infections, asthma, COPD, tuberculosis, bronchiectasis, pulmonary embolism, and numerous other conditions.

The significance lies particularly in symptoms that are persistent, progressive, unexplained, or occurring in a person with important risk factors.

Persistent Cough

A cough is one of the most common symptoms associated with lung cancer.

A tumor may irritate the bronchial tree or partially obstruct an airway, stimulating cough receptors. A patient with a pre-existing chronic cough may notice a change in its character, frequency, or severity.

A new persistent cough should not automatically be attributed to smoking, allergy, or a minor respiratory infection if it fails to improve as expected.

Hemoptysis

Hemoptysis means coughing up blood originating from the lower respiratory tract.

Lung cancer can cause hemoptysis when a tumor invades bronchial blood vessels or damages the airway lining.

Although hemoptysis has many causes, including infection and bronchiectasis, unexplained or recurrent blood in sputum requires medical assessment.

Large-volume hemoptysis can become a medical emergency because blood may obstruct the airway and impair oxygenation.

Shortness of Breath

Dyspnea can occur when a tumor obstructs an airway, causes lung collapse, produces pleural effusion, or reduces functional lung capacity.

Advanced disease can produce severe breathlessness through multiple mechanisms, including metastatic disease, anemia, infection, pulmonary embolism, or treatment-related complications.

Chest Pain

Chest pain may develop when a tumor involves the pleura, chest wall, ribs, or other nearby structures.

Pain characteristics vary depending on the anatomical structures involved. Pleural irritation may produce pain that worsens with deep inspiration or coughing.

Chest pain in a patient with suspected lung cancer should always be evaluated carefully because it may also indicate cardiovascular disease or other urgent conditions.

Hoarseness

Hoarseness may occur when a tumor affects the recurrent laryngeal nerve, which supplies the vocal cords.

Persistent unexplained hoarseness is therefore an important clinical feature, particularly when associated with other respiratory or systemic symptoms.

Recurrent Pneumonia

A tumor obstructing a bronchus can interfere with normal drainage and ventilation of the distal lung. This may predispose the patient to repeated infections.

Sometimes the apparent pneumonia improves temporarily with antibiotics but repeatedly returns in the same anatomical region.

Recurrent or non-resolving pneumonia should prompt consideration of an underlying obstructing lesion.

Unexplained Weight Loss

Cancer can produce profound metabolic changes. Increased energy expenditure, inflammatory mediators, reduced appetite, altered metabolism, and treatment effects can all contribute to weight loss.

Unintentional weight loss is a clinically important warning sign, especially when accompanied by persistent respiratory symptoms.

Fatigue

Cancer-related fatigue can be substantial and is often disproportionate to physical activity.

Possible contributors include inflammation, anemia, poor nutrition, sleep disturbance, advanced disease, psychological stress, and treatment effects.

Advanced and Metastatic Symptoms

Once lung cancer spreads beyond the primary site, symptoms may depend on the organs involved.

Brain Metastases

Brain involvement may cause:

• Headache
• Seizures
• Weakness
• Sensory disturbances
• Speech problems
• Balance problems
• Cognitive or behavioral changes
• Altered consciousness

Neurological symptoms in a patient with lung cancer require prompt assessment.

Bone Metastases

Bone metastases may cause persistent or localized bone pain, pathological fractures, or spinal cord compression.

Spinal cord compression is an oncological emergency because delayed treatment can result in permanent neurological disability.

Liver Metastases

Liver involvement may cause:

• Abdominal discomfort
• Loss of appetite
• Weight loss
• Abnormal liver function tests
• Jaundice in advanced disease

Adrenal Metastases

The adrenal glands are common sites of metastasis in lung cancer. Many adrenal metastases remain clinically silent, but extensive bilateral involvement can rarely contribute to adrenal insufficiency.

Paraneoplastic Syndromes

Lung cancer can produce systemic manifestations that are not caused simply by direct tumor invasion or metastasis. These are called paraneoplastic syndromes.

They result from substances produced by the tumor or from immune-mediated effects.

Important examples include:

Hypercalcemia

Squamous cell carcinoma may produce parathyroid hormone-related protein, leading to increased serum calcium.

Symptoms of significant hypercalcemia may include:

• Weakness
• Constipation
• Nausea
• Excessive thirst
• Frequent urination
• Confusion
• Reduced consciousness in severe cases

SIADH

Small cell lung cancer may produce inappropriate antidiuretic hormone secretion, causing syndrome of inappropriate antidiuretic hormone secretion (SIADH).

This can lead to dilutional hyponatremia.

Symptoms depend on severity and rate of sodium reduction and may include headache, nausea, confusion, seizures, or altered consciousness.

Ectopic ACTH Production

SCLC can produce ectopic adrenocorticotropic hormone, resulting in Cushing syndrome.

Possible features include:

• Hyperglycemia
• Hypertension
• Muscle weakness
• Weight gain
• Hypokalemia
• Characteristic body-fat distribution

Digital Clubbing and Hypertrophic Osteoarthropathy

Some lung cancers are associated with digital clubbing and hypertrophic osteoarthropathy.

Clubbing involves enlargement of the distal portions of the fingers and changes in the nail-bed angle. When associated with painful periosteal new bone formation, the condition is called hypertrophic osteoarthropathy.

Physical Examination

The physical examination begins with a complete history and general assessment.

Important findings may include:

• Weight loss
• Cachexia
• Clubbing
• Enlarged lymph nodes
• Reduced breath sounds
• Localized crackles
• Wheezing
• Signs of pleural effusion
• Features of airway obstruction
• Neurological abnormalities
• Bone tenderness

Supraclavicular lymphadenopathy can be particularly important because it may represent regional or metastatic lymph-node involvement.

Physical examination alone cannot establish the diagnosis, but it helps determine the severity of disease and guides further investigation.

Initial Investigations

When lung cancer is suspected, diagnostic evaluation usually combines imaging, laboratory testing, tissue sampling, and staging investigations.

A typical diagnostic pathway may include:

1. Clinical history and physical examination
2. Chest imaging
3. Contrast-enhanced CT
4. Tissue biopsy
5. Histopathological examination
6. Molecular and biomarker testing when appropriate
7. PET-CT or other staging imaging
8. Brain imaging in selected patients
9. Pulmonary and functional assessment when surgery is considered

NCI emphasizes that imaging and biopsy are central to diagnosis and staging, while additional investigations determine whether disease has spread within the chest or to distant organs.

Chest X-Ray

A chest X-ray is often one of the first imaging studies performed when respiratory symptoms are investigated.

It may reveal:

• A pulmonary mass
• Hilar enlargement
• Lobar collapse
• Pleural effusion
• Persistent infiltrates
• Enlarged mediastinal structures

However, a normal chest X-ray does not completely exclude lung cancer, particularly when the lesion is small or located in an anatomically difficult region.

Therefore, persistent clinical suspicion may require CT imaging even when the initial X-ray is unrevealing.

Computed Tomography

CT chest provides much greater anatomical detail than plain radiography.

It can characterize:

• Tumor size
• Tumor location
• Airway involvement
• Chest-wall invasion
• Mediastinal structures
• Pleural disease
• Enlarged lymph nodes
• Additional pulmonary nodules

Contrast-enhanced CT can provide additional information about vascular and soft-tissue structures.

CT is an important component of both diagnosis and staging.

PET-CT

Positron emission tomography combined with CT can help identify metabolically active disease throughout the body.

Many malignant tumors demonstrate increased glucose metabolism and therefore increased uptake of fluorodeoxyglucose.

PET-CT can assist in:

• Identifying the primary tumor
• Assessing lymph-node involvement
• Detecting distant metastases
• Selecting appropriate biopsy sites
• Planning treatment

However, increased metabolic activity is not specific to cancer. Infections and inflammatory processes can also produce increased uptake.

Bronchoscopy

Bronchoscopy allows direct visualization of the tracheobronchial tree.

A flexible bronchoscope can be introduced through the nose or mouth and advanced into the airways.

Bronchoscopy may allow clinicians to:

• Visualize an endobronchial lesion
• Obtain biopsy samples
• Collect bronchial washings
• Perform brush cytology
• Assess airway obstruction
• Control certain types of bleeding
• Obtain material for microbiological testing

The procedure is particularly useful for centrally located tumors.

Needle Biopsy

A peripheral pulmonary lesion may be sampled using image-guided percutaneous needle biopsy.

CT guidance can help position the needle accurately within the abnormal area.

Potential complications include pneumothorax and bleeding, so the risks and benefits must be considered before the procedure.

Lymph Node Sampling

Determining whether cancer has spread to mediastinal or hilar lymph nodes is essential for staging.

Sampling may be performed using techniques such as endobronchial ultrasound-guided transbronchial needle aspiration, mediastinoscopy, or other approaches depending on tumor location and clinical circumstances.

Histopathology

The biopsy specimen is examined by a pathologist.

Microscopic examination determines the type and characteristics of the cancer.

Histological diagnosis is important because different types of lung cancer have different biological behaviors and treatment approaches.

Immunohistochemistry may be used when the microscopic appearance alone is insufficient to establish the tumor type.

Molecular and Biomarker Testing

Modern lung cancer diagnosis increasingly extends beyond conventional microscopy.

Molecular testing can identify genetic alterations that may be targeted therapeutically.

Depending on tumor type and clinical context, testing may evaluate alterations such as:

• EGFR
• ALK
• ROS1
• BRAF
• KRAS
• MET
• RET
• NTRK

Testing may also assess PD-L1 expression because it can help guide immunotherapy decisions.

The purpose of molecular profiling is to identify vulnerabilities within cancer cells that can be exploited therapeutically.

Staging of Lung Cancer

Staging determines how far the cancer has progressed and is one of the most important factors guiding treatment.

For NSCLC, the TNM system is widely used.

TNM represents:

• T — Tumor: characteristics and extent of the primary tumor
• N — Nodes: involvement of regional lymph nodes
• M — Metastasis: presence or absence of distant spread

The combination of T, N, and M categories produces an overall stage.

Broadly, NSCLC may be described as stage 0, I, II, III, or IV, with subdivisions within several stages.

Early-stage disease is generally more localized and may be potentially curable with local treatment. Advanced disease may require systemic therapy.

Stage 0

Stage 0 represents very early non-invasive disease, often called carcinoma in situ.

At this stage, malignant cells remain confined to the epithelial layer without invasion into deeper tissues.

Appropriate localized treatment can potentially be curative.

Stage I

Stage I NSCLC is generally confined to the lung without regional lymph-node involvement.

Surgery is commonly the primary treatment when the patient is medically suitable.

For selected patients who cannot undergo surgery, stereotactic body radiation therapy may provide an alternative local treatment.

Stage II

Stage II disease may involve a larger primary tumor and/or regional lymph nodes, depending on the specific TNM classification.

Treatment frequently involves surgery combined with additional systemic therapy when appropriate.

The exact treatment depends on tumor characteristics, lymph-node status, molecular findings, and the patient's overall condition.

Stage III

Stage III lung cancer represents locally advanced disease.

Tumors may involve mediastinal lymph nodes or invade nearby structures.

Some stage III tumors are potentially resectable, whereas others cannot be safely removed surgically.

Treatment may involve combinations of chemotherapy, radiation therapy, immunotherapy, and surgery in carefully selected patients.

Stage IV

Stage IV disease indicates distant metastatic spread or certain patterns of extensive disease.

Common metastatic sites include:

• Brain
• Bone
• Liver
• Adrenal glands
• Other areas of the lungs
• Distant lymph nodes

Treatment is usually systemic, although radiation or surgery may sometimes be used for selected lesions or symptom control.

In advanced NSCLC, molecular and biomarker information can strongly influence therapy.

Treatment Principles

Lung cancer treatment must be individualized.

Important considerations include:

• Histological type
• Stage
• Molecular profile
• PD-L1 status when relevant
• Tumor location
• Resectability
• Lung function
• Cardiovascular status
• Performance status
• Other medical conditions
• Previous treatment
• Patient preferences

Treatment may involve a single modality or multiple approaches.

The major treatment categories are:

• Surgery
• Radiation therapy
• Chemotherapy
• Targeted therapy
• Immunotherapy
• Endobronchial treatments
• Supportive and palliative care

NCI identifies surgery, radiation, chemotherapy, targeted therapy, and immunotherapy among the major treatment approaches for NSCLC.

Surgical Treatment

Surgery offers an important possibility of long-term disease control or cure in selected patients with localized NSCLC.

The extent of surgery depends on tumor size, location, lung function, and other clinical factors.

Possible procedures include:

Wedge Resection

A wedge resection removes the tumor along with a small surrounding margin of normal lung tissue.

Segmentectomy

Segmentectomy removes an anatomical segment of a lung lobe.

Lobectomy

Lobectomy involves removal of an entire lung lobe.

It has traditionally been a standard surgical approach for many operable early-stage NSCLC tumors.

Pneumonectomy

Pneumonectomy involves removal of an entire lung.

It is generally reserved for selected tumors that cannot be adequately removed with a smaller resection.

Sleeve Resection

Sleeve resection can remove a tumor involving a major bronchus while preserving more functioning lung tissue than pneumonectomy in appropriate cases.

The choice of procedure depends heavily on tumor anatomy and the surgeon's assessment.

Radiation Therapy

Radiation therapy uses high-energy radiation to damage cancer cells and prevent them from continuing to grow.

It may be used with curative intent, as an alternative to surgery in selected patients, as part of multimodal therapy, or for palliation.

Modern techniques can deliver radiation more precisely while attempting to minimize exposure of surrounding healthy tissues.

Stereotactic body radiation therapy (SBRT) can deliver highly focused doses to selected early-stage lung tumors, particularly in patients who are not surgical candidates.

Radiation may also be used to treat metastatic disease, including painful bone lesions or brain metastases.

Chemotherapy

Chemotherapy uses cytotoxic drugs that interfere with cancer-cell growth and division.

Examples used in lung cancer include platinum agents such as cisplatin or carboplatin combined with other agents depending on the histology and clinical situation.

Chemotherapy may be used:

• Before surgery
• After surgery
• With radiation
• With immunotherapy
• For advanced metastatic disease

Common adverse effects can include:

• Nausea
• Vomiting
• Fatigue
• Myelosuppression
• Hair loss
• Increased infection risk
• Peripheral neuropathy
• Kidney toxicity with certain agents

The specific adverse-effect profile depends on the drugs used.

Targeted Therapy

Targeted therapy is designed to interfere with specific molecular abnormalities that promote cancer growth.

For example, tumors with particular EGFR alterations may respond to EGFR-targeted drugs, while tumors with certain ALK alterations may respond to ALK inhibitors.

Targeted therapy is an important component of precision medicine because treatment is selected according to the tumor's molecular profile.

Targeted therapies may produce dramatic responses in appropriately selected patients, although resistance can eventually develop.

Cancer cells may acquire additional molecular alterations that allow them to escape the effect of the original treatment. This is one reason repeat molecular testing may sometimes be considered when disease progresses.

Immunotherapy

Immunotherapy aims to help the immune system recognize and attack cancer cells.

Cancer can develop mechanisms that suppress immune responses. Some lung cancers exploit immune checkpoint pathways to avoid immune destruction.

Checkpoint inhibitors can interfere with these suppressive pathways.

Immunotherapy may be used alone or in combination with chemotherapy or other treatments depending on the tumor's characteristics and stage.

Immune-related adverse effects differ from conventional chemotherapy toxicities because the activated immune system can attack normal organs.

Potential complications include:

• Pneumonitis
• Colitis
• Hepatitis
• Thyroid dysfunction
• Adrenal insufficiency
• Skin inflammation
• Other immune-mediated disorders

Patients receiving immunotherapy therefore require appropriate monitoring.

Treatment of Small Cell Lung Cancer

SCLC behaves differently from NSCLC and usually requires systemic therapy because microscopic metastatic disease is common even when the visible tumor appears localized.

Chemotherapy is a central component of treatment.

Radiation therapy may be incorporated depending on disease extent and clinical circumstances.

Because SCLC has a particular tendency to spread to the brain, brain imaging is an important part of assessment, and radiation strategies may be considered in appropriate patients.

Treatment approaches continue to evolve as clinical trials investigate new combinations and therapies.

Treatment According to Stage

Early-stage NSCLC is generally approached with the goal of cure.

Surgery may be performed when the tumor is technically resectable and the patient's cardiopulmonary status permits an operation. Additional chemotherapy, immunotherapy, or targeted therapy may be considered based on pathological and molecular characteristics.

For patients unable to undergo surgery, definitive radiation, including SBRT in selected early-stage cases, may be appropriate.

Locally advanced disease often requires multimodal treatment. Chemotherapy and radiation may be combined, sometimes followed by immunotherapy or surgery in selected circumstances.

Metastatic disease is usually managed primarily with systemic treatment. Molecular alterations and biomarker results can determine whether targeted therapy, immunotherapy, chemotherapy, or combinations are appropriate.

Complications of Lung Cancer

Lung cancer can produce complications from local tumor growth, metastatic spread, paraneoplastic effects, or treatment.

Important complications include:

• Airway obstruction
• Post-obstructive pneumonia
• Atelectasis
• Pleural effusion
• Pericardial effusion
• Superior vena cava syndrome
• Hemoptysis
• Respiratory failure
• Brain metastases
• Bone metastases
• Spinal cord compression
• Hypercalcemia
• SIADH
• Thromboembolic disease

Some complications can become life-threatening and require urgent management.

Pleural Effusion

A tumor can involve the pleura and cause accumulation of fluid in the pleural cavity.

A malignant pleural effusion may cause:

• Progressive breathlessness
• Chest heaviness
• Cough
• Reduced exercise tolerance

Thoracentesis can be used both diagnostically and therapeutically.

If the effusion repeatedly returns, additional interventions may be necessary depending on the patient's condition and goals of care.

Superior Vena Cava Syndrome

A centrally located lung tumor or enlarged mediastinal lymph nodes can compress or invade the superior vena cava.

This may cause:

• Facial swelling
• Neck swelling
• Upper-limb swelling
• Distended neck veins
• Shortness of breath
• Headache

Severe cases can become urgent because venous obstruction can compromise cerebral and airway circulation.

Airway Obstruction

Tumors arising within or adjacent to major bronchi can narrow the airway.

This may produce wheezing, breathlessness, cough, recurrent pneumonia, or lobar collapse.

In selected patients, bronchoscopic interventions such as stenting, laser therapy, electrocautery, cryotherapy, or other techniques may help restore airway patency and improve symptoms. NCI lists several endobronchial approaches among treatment options in appropriate circumstances.

Prognosis

Prognosis varies widely among people with lung cancer.

Important prognostic factors include:

• Cancer type
• Stage
• Tumor biology
• Molecular alterations
• Lymph-node involvement
• Presence of metastases
• Response to treatment
• General health
• Lung function
• Performance status

Localized disease generally offers substantially more treatment options with curative intent than widely metastatic disease.

However, staging alone does not completely predict an individual's outcome. Advances in targeted therapy and immunotherapy have created additional treatment possibilities for selected patients with advanced disease.

Lung Cancer Screening

Screening is intended to identify lung cancer before symptoms develop, when treatment may be more effective.

Screening is not appropriate for every person. Eligibility depends on factors such as age and cumulative smoking exposure and differs according to national guidelines.

For people who meet appropriate criteria, low-dose CT (LDCT) is the established screening approach in many guidelines.

Screening should not be confused with diagnostic evaluation. A person who already has concerning symptoms generally requires diagnostic assessment rather than simply entering a screening program.

Prevention

A substantial proportion of lung cancers are potentially preventable.

The most important preventive measure is avoiding tobacco use.

For people who smoke, quitting at any stage can reduce future health risks. The earlier smoking cessation occurs, the greater the long-term benefit.

Other preventive strategies include:

• Avoiding second-hand smoke
• Testing for radon where appropriate
• Following occupational safety regulations
• Using appropriate respiratory protection
• Reducing exposure to known carcinogens
• Maintaining a healthy lifestyle
• Seeking medical evaluation for persistent respiratory symptoms

Because lung cancer can occur in nonsmokers, prevention should not be reduced to smoking cessation alone.

Smoking Cessation and Lung Cancer

Smoking cessation is important even after a lung cancer diagnosis.

Continuing to smoke may increase the risk of treatment complications and other smoking-related diseases. Quitting can improve overall health and may improve the ability to tolerate cancer treatment.

Smoking cessation should therefore be incorporated into comprehensive cancer care.

Professional counseling, behavioral interventions, and evidence-based pharmacological treatments can improve the likelihood of successful cessation.

Role of Nutrition

Cancer and its treatment can significantly affect nutritional status.

Patients may experience:

• Loss of appetite
• Taste changes
• Nausea
• Difficulty swallowing
• Fatigue
• Weight loss
• Muscle wasting

Severe weight and muscle loss can contribute to cancer cachexia, a complex metabolic syndrome that cannot be corrected simply by increasing calorie intake.

Nutritional assessment should therefore form part of supportive cancer care.

Psychological Impact

A lung cancer diagnosis can produce substantial emotional distress.

Patients may experience:

• Fear
• Anxiety
• Depression
• Uncertainty
• Anger
• Social isolation
• Financial stress
• Concerns about family responsibilities

The psychological impact can affect treatment adherence, sleep, appetite, and quality of life.

Support from family, oncology teams, mental-health professionals, support groups, and palliative-care specialists can be valuable.

Palliative and Supportive Care

Palliative care is not synonymous with giving up on cancer treatment.

It focuses on improving quality of life by addressing symptoms and supporting patients and families throughout serious illness.

Symptoms that may require supportive management include:

• Pain
• Breathlessness
• Cough
• Fatigue
• Nausea
• Anxiety
• Poor appetite
• Sleep disturbance

Palliative care can be provided alongside active cancer treatment.

For advanced disease, symptom control becomes especially important because the goals of treatment may shift from eliminating the cancer to controlling its growth, prolonging life, maintaining function, and maximizing comfort.

Follow-Up After Treatment

Patients who complete treatment require continued follow-up.

Follow-up may include:

• Clinical assessment
• Imaging
• Monitoring for recurrence
• Evaluation of treatment complications
• Assessment of nutritional status
• Smoking cessation support
• Rehabilitation
• Psychological support

Follow-up schedules vary according to the type and stage of cancer and the treatment received.

Recurrence may occur locally, regionally, or at distant sites.

Recurrence

Cancer recurrence means that cancer returns after a period during which it could not be detected or was considered controlled.

Recurrence may be:

• Local
• Regional
• Distant

The management of recurrent lung cancer depends on the original cancer type, previous treatments, location of recurrence, molecular characteristics, and overall health.

Some patients may be candidates for additional surgery or radiation, whereas others may require systemic therapy.

Current Direction of Lung Cancer Research

Lung cancer research is increasingly focused on precision medicine, molecular profiling, immune-based therapies, early detection, resistance mechanisms, and improved treatment combinations.

Researchers continue to investigate new targeted therapies and immunotherapies, as well as strategies to identify cancer earlier.

One important area of research involves understanding why tumors initially respond to targeted treatment but later become resistant.

Another major focus is improving screening and early diagnosis so that cancers can be identified before they become advanced.

Researchers are also investigating blood-based approaches, including circulating tumor DNA and other biomarkers, although their roles continue to evolve.

Clinical trials remain an important pathway for evaluating new treatments and combinations. NCI notes that research continues across all stages of lung cancer, including newer targeted and immunotherapy approaches.

Key Clinical Warning Signs

Certain symptoms should prompt medical evaluation rather than prolonged self-treatment.

Important warning signs include:

• Persistent or worsening cough
• Coughing up blood
• Unexplained weight loss
• Persistent chest pain
• Progressive breathlessness
• Persistent hoarseness
• Recurrent pneumonia
• Unexplained fatigue
• New neurological symptoms in a person at risk
• Persistent respiratory symptoms in a long-term smoker

These symptoms do not prove lung cancer, but they warrant appropriate clinical assessment.

Differential Diagnosis

Many conditions can resemble lung cancer clinically or radiologically.

Important differential diagnoses include:

• Tuberculosis
• Bacterial pneumonia
• Lung abscess
• Fungal infection
• Sarcoidosis
• Pulmonary embolism
• COPD-related changes
• Bronchiectasis
• Benign pulmonary nodules
• Metastatic tumors from other organs
• Lymphoma
• Inflammatory lung disease

This is why a suspicious lung lesion should not be labeled as cancer solely from symptoms or a single imaging study.

Definitive diagnosis generally requires appropriate tissue sampling and pathological evaluation when clinically indicated.

Important Differences Between NSCLC and SCLC

NSCLC and SCLC differ in several important respects.

NSCLC is more common and includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. It may be localized for longer periods, making surgery important for appropriately selected early-stage patients. Molecular testing is particularly important because actionable alterations can guide targeted therapy.

SCLC is strongly associated with smoking, tends to grow rapidly, and commonly spreads early. Systemic therapy is therefore central to management.

The distinction between these two major categories is one of the first major steps after tissue diagnosis because it influences staging and treatment planning.

Importance of a Multidisciplinary Team

Modern lung cancer management often involves multiple specialists.

The team may include:

• Pulmonologist
• Medical oncologist
• Radiation oncologist
• Thoracic surgeon
• Radiologist
• Pathologist
• Molecular pathologist
• Respiratory therapist
• Oncology nurse
• Dietitian
• Physiotherapist
• Palliative-care specialist
• Mental-health professional

Multidisciplinary discussion can help integrate imaging, pathology, molecular findings, surgical options, radiation planning, and systemic treatment.

This is particularly important for complex stage III disease and tumors located near major blood vessels, airways, the heart, or other critical structures.

Patient Education

Education is an essential component of lung cancer care.

Patients should understand:

• The exact type of cancer
• The stage
• Whether it has spread
• Molecular test results when applicable
• The purpose of proposed treatment
• Expected benefits
• Potential adverse effects
• Warning symptoms requiring urgent medical attention
• Follow-up requirements

Patients should also be encouraged to ask questions about treatment alternatives and, when appropriate, obtain a second opinion.

NCI notes that some patients choose to seek a second opinion, particularly to confirm the diagnosis and treatment strategy.

Importance of Early Detection

The earlier lung cancer is identified, the greater the possibility of treating it with a curative strategy.

Early tumors may be amenable to surgical removal or highly focused radiation therapy.

By contrast, metastatic disease generally requires systemic therapy because cancer cells have spread beyond the original site.

This difference explains why appropriate screening of high-risk populations and timely investigation of suspicious symptoms are so important.

Conclusion

Lung cancer is a complex and biologically diverse malignancy that encompasses several distinct diseases rather than a single uniform condition. Although tobacco exposure remains the leading preventable risk factor, lung cancer can also develop in people who have never smoked through a combination of environmental, occupational, genetic, and biological factors. Its clinical manifestations range from subtle persistent respiratory symptoms to severe local complications, systemic effects, paraneoplastic syndromes, and symptoms caused by distant metastases.

Diagnosis requires integration of clinical assessment, imaging, tissue sampling, histopathology, staging, and, increasingly, molecular and biomarker testing. The distinction between NSCLC and SCLC is fundamental because their biological behavior and therapeutic approaches differ.

Treatment has evolved considerably beyond traditional chemotherapy. Surgery and radiation remain essential for appropriately selected localized disease, while chemotherapy, targeted therapy, and immunotherapy have become important components of treatment across different stages. Molecular profiling has made it possible to identify specific vulnerabilities in some tumors and select therapies more precisely.

Prevention, smoking cessation, occupational safety, appropriate screening, early investigation of suspicious symptoms, and access to modern multidisciplinary cancer care all contribute to better outcomes. For patients with advanced disease, supportive and palliative care remain essential for controlling symptoms and maintaining quality of life.

The most important message is that persistent respiratory symptoms should not automatically be dismissed as a routine infection, smoking-related cough, or another benign condition. Appropriate medical assessment can help distinguish common respiratory diseases from potentially serious conditions and, when cancer is present, may allow diagnosis at a stage when more effective treatment options are available.